US fashion brand Thom Browne will launch a new perfume line consisting of six variants in South Korea after seeing a 30 percent on-year growth this year.
The perfumes to be released will include Vetyver Absolute, and the Vetyver and Cucumber.
The fragrances contain a high concentration of Haitian Vetyver oil and its vetyver blend serves as the base signature of the products.
Earlier this year, Thom Browne collaborated with Samsung Electronics to release a limited edition of the Galaxy Z Flip, which sold out in hours.
The fashion brand also enjoyed a rise in popularity in South Korea last year when members of the boy band BTS wore their suits at a press conference for their Wembley Stadium concert.
According to Samsung C&T Corp., the South Korean distributor of the fashion brand, they are anticipating a closer relationship with Korean customers and expand their lifestyle business with the introduction of the fragrance line.


Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue
Google Secures Pentagon AI Deal for Classified Projects
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 



